Cancer cells are susceptible to oncolytic viruses, albeit variably. Human adenoviruses (HAdVs) are widely used oncolytic agents, engineered to produce progeny within the tumor, and elicit bystander effects. We searched for host factors enhancing bystander effects, and conducted a targeted RNA-interference screen against guanine-nucleotide exchange factors (GEFs) of small GTPases. We show that unfolded protein response (UPR), which is readily inducible in aggressive tumor cells, enhances melanoma or epithelial cancer cell killing upon HAdV infection. UPR was triggered by knock-down of Golgi Brefeldin-A resistant guanine-nucleotideexchange factor-1 (GBF-1), or the GBF-1 inhibitor Golgicide A (GCA), and stimulated HAdV infection. GBF-1 is a GEF for ADP-ribosylation factors (Arfs) regulating ER to Golgi and intra-Golgi transport. Cells treated with GCA enhanced HAdV-induced cytopathic effects in epithelial and melanoma cancer but not normal cells, if the drug was applied several hours prior to HAdV inoculation. This was shown by real-time label-free impedance measurements using xCELLigence™. 
IMPORTANCE
Cancer is difficult to combat. A wide range of oncolytic viruses show promise for killing cancer cells. Yet, the efficacy of oncolytic killing is low. We searched for host factors enhancing adenovirus cancer cell killing, and found that the knock-down of GBF-1 (Golgi Brefeldin-A resistant guanine-nucleotide-exchange factor-1) or chemical inhibition of GBF-1 enhanced adenovirus infection by triggering the IRE-1/XBP-1 branch of the unfolded protein response (UPR). IRE-1/XBP-1 promote cell survival, and enhanced the levels of the adenoviral immediate early gene product E1A, virus spreading, and killing of cancer cells. Aggressive tumor cells depend on a readily inducible UPR, and hence present prime targets for a combined strategy involving adenoviruses and small chemicals inducing UPR.
INTRODUCTION
Cancer is a devastating multifactorial disease, and difficult to combat owing to genomic instability, uncontrolled proliferation, dissemination, and poor immunologic control (for reviews, see 8, 25) . Oncolytic viruses are an emerging therapeutic practice (reviewed in 1, 53) . Oncolytic viral therapy takes advantage of the fact that many enveloped and non-enveloped viruses destroy host cells as parts of their replication strategy. Oncolytic viruses include herpes virus, measles virus, vesicular stomatitis virus, influenza A virus, Newcastle disease virus, vaccinia virus, poliovirus, parvovirus and adenovirus. Currently, human adenoviruses (HAdVs) are the most widely used oncolytic agents, engineered to produce progeny within the tumor, and kill tumor rather than normal cells (20) .
Oncolytic viruses directly kill cancer cells, and may trigger an immune response against cancer specific or viral epitopes presented on major histocompatibility class 1 protein to immune cells. This poses the problem that an oncolytic virus can be eliminated by the immune system before reaching full efficacy, for example, if the host is not tolerant against immune-dominant viral antigens. Since immunetolerance against dominant viral antigens is rare, other ways are explored to enhance the oncolytic efficacy of viruses. For example, treatments with biological agents, chemicals or physical induction of stress sensitize tumor cells to be killed by oncolytic viruses (3, 67) . In some instances, stress induction leads to inhibition of virus replication, for example radiation therapy attenuates vaccinia virus infection (35). Alternatively, inhibition of cell stress can enhance oncolysis, for example blockage of ER stress augments rhabdovirus oncolysis (40) .
Here, we report that chemical or genetic inhibition of GBF-1 (Golgi Brefeldin-A resistant guanine-nucleotide-exchange factor-1) activates unfolded protein response (UPR) from the ER, and enhances gene expression from adenoviruses HAdV-C5 and B3. GBF-1 inhibition boosts HAdV-induced cell killing, and viral dissemination in human lung epithelial or melanoma-derived cancer cells. GBF-1 is a cis-Golgi guanine nucleotide exchange factor (GEF) for ADP ribosylation factors (ARFs), and regulates ER-Golgi and intra-Golgi membrane traffic (12, 74) . It is widely expressed in human cells, and controls the dynamics of ARF and COP-I at ER-Golgi interface (41, 63) . Notably, GBF-1 depletion by RNAi induces the UPR by locating site specific protease (SP) 1 and 2 from Golgi to ER, and proteolytic activation of activating transcription factor 6 (ATF-6) (11).
HAdVs are wide-spread non-enveloped DNA viruses causing mild, self-limiting infections in immune-competent individuals (21) . Species B and C HAdVs target the urogenital and respiratory tracts, and have been extensively developed into vectors for clinical therapy (20) . They attach to host cells via the coxsackievirus adenovirus receptor (CAR), CD46 or desmoglein-2 and in most cases integrin secondary receptors (71) . This triggers initial steps of virus uncoating, internalization and endosomal membrane rupture by pH-independent mechanisms (5, 46, 61) .
Cytosolic viruses are transported by dynein/dynactin and microtubules to the nuclear pore complex, where kinesin-mediated virus disassembly and disruption of the nuclear pore complex occur, and viral DNA is imported into the nucleus (4, 60, 62, 70) . Expression of the early region 1A (E1A) genes from episomal viral DNA controls a range of host and viral genes (14, 48) . E1A starts the viral gene expression and genome replication programs, which drive viral immune escape and, ultimately, the release of progeny viruses from the nucleus upon cell lysis (66). Yet, the clinical oncolytic efficacy of adenoviruses and other virus-derived oncolytic vectors has been modest (44, 65) . This is paralleled by a recent observation from 2-dimensional cell cultures showing that inefficient viral transmission correlates with low events of lytic infection (72) . The results here show that induction of UPR through the IRE-1 sensor and the XBP-1 transcription factor leads to enhanced viral cytotoxicity in primary human cancer cells. This is a hereto unknown pathway leading from ER stress and host transcriptional response to enhanced viral gene expression and oncolysis.
MATERIALS AND METHODS

Cells and viruses
Cells and viruses were grown as described before (5, 19, 39, 47) . A549 cells (15, 38) , and WI38 is a human diploid cell line derived from normal embryonic lung tissue (American Type Culture Collection).
XBP-1 -/-and wildtype control mouse embryonal fibroblasts (MEFs, obtained from Laurie Glimcher, Weill Cornell Medical College) were maintained as described (36) .
The replicating HAdV-C5_wt and HAdV-C2-dE3B_GFP were grown in A549 cells as described (22, 23, 47) . Non-replicating HAdV-C5-dE1_GFP (19, 47) and HAdV-B3-dE1_GFP (57) containing GFP under the control of the CMV major immediate early promoter were grown in 911 cells. The formation of HAdV-C2-dE3B_GFP progeny was as described (49, 72) . Cell viability was measured by resazurin as described (33). Infectious titer of HAdV-C5_wt and HAdV-C2-dE3B_GFP was determined on A549 cells, and that of HAdV-C5-dE1_GFP on 911 cells.
Transfections and infections
Knockdown experiments were performed in 96-well imaging plates (Greiner Bioone) using reverse transfection: siRNA (1 pmol/well diluted in 5 µl ddH 2 pipeline (according to 7) were used to quantify the average nuclear intensity of the GFP and protein VI signals, which were used as measures of infection efficiency.
The spreading of HAdV-C2-dE3B_GFP was analyzed by time lapse fluorescence microscopy as described (72) . A detailed description of the imaging procedures is available on request. Human rhinovirus species A type A1 (HRV-A1A) infections were analyzed 7 h pi as described (34).
In Golgicide A (GCA, Sigma) experiments, the cells were pretreated with the drug or its solvent DMSO for 5 h. GCA concentration in all experiments was 20 µM. To determine virus progeny formation from control vs GCA-treated cells, HAdV-C2-dE3B_GFP (0.008 infectious units/cell) was added to confluent A549 cells and progeny collected from the clarified culture medium, and from cells by Freon extraction 40 h post infection (pi). Samples were titrated on HeLa-ATCC cells grown on 96-well imaging plates using serial 10-fold dilutions of cell extracts or culture supernatants, at 18 h post infection samples were fixed, DAPI-stained and GFP positive cells were counted from wells that had lower than 100% infection. One GFP positive cell was scored as one infectious particle.
Cell impedance measurements by xCELLigence TM and cell counting
The xCELLigence TM system (Roche Applied Science and ACEA Biosciences)
consists of four components, analyzer, device station, control unit with software and E-plates (disposable E-Plate 16). The device was used as described by the supplier (59). E-plates have a gold plated sensor array at the bottom, which measures electrical impedance across the plate. Impedance is recorded in terms of a dimensionless quantity termed cell index (CI). For background measurements, 100
µl of culture medium was added to the E-plate well, equilibrated at 37˚C and supplemented with 6,500 or 25,000 cells at 37˚C. Forty-eight hours later, inhibitor was added to the cells for 5 h, followed by the addition of virus. Impedance was recorded every 15 minutes until the CI value reached background levels. 
XBP-1 splicing
cDNA was synthesized from total RNA extracts and RT-PCR carried out with primers spanning XBP-1 as described (42) . PCR products were restriction digested with PstI and analyzed by 2% agarose gel electrophoresis.
GCA effects on gene expression from transfected or integrated DNA
293T cells were treated with GCA for 5 h, and E1A levels were scored from cell extracts by immunoblotting with M73 anti-E1A antibody. pMAX-EGFP plasmid DNA (Amaxa) driving GFP expression from the CMV promoter was transfected into A549 cells using Neon transfection (Life Technologies). After 24 h, transfected cells were treated with GCA for 5 h, washed, stained with Hoechst 33342, live imaged by automated high-throughput microscopy 5 or 21 h after drug washout, and single cells were analyzed for GFP expression by CellProfiler using a nuclear DAPI mask extended by 5-pixels to account for cytoplasmic GFP.
Effect of GCA on HAdV-C5 binding to cells
Cells grown on Alcian blue-coated coverslips were treated with GCA (20 µM) for 12 or 0.5 h followed by inoculation with atto 565-labelled HAdV-C5_wt at cold for 30 min, washing and 5 min pulse at 37°C. Confocal maximal intensity projections were analyzed with a custom made Matlab TM script, in which the cell outline was manually segmented using boosted DAPI channel. The number of virus particles per cell was counted within the cell outlines and analyzed using Graphpad Prism, and MannWhitney test for statistics.
Statistical analyses
Results for infection assays are shown as means from 3 parallel wells, unless otherwise indicated and experiments were repeated 3 to 4 times.
RESULTS
Inhibition of GBF-1 enhances post entry steps in HAdV infection
In search for host factors enhancing bystander effects and cell killing upon viral infection, we conducted an RNA-interference screen against guanine-nucleotide exchange factors (GEFs) of small GTPases implicated in secretion. The knock-down of GBF-1 stimulated adenovirus infection, measured with HAdV-C5 wild type (wt), replication-defective HAdV-C5-dE1_GFP and replication-competent HAdV-C2-dE3B_GFP ( Fig. 1 A) . In both HAdV-C5-dE1_GFP and HAdV-C2-dE3B_GFP, GFP was under the major early cytomegalovirus (CMV) promoter. The extent of infection boost was between threefold and tenfold in different independent experiments and the boost with different GBF-1 siRNAs correlated with GBF-1 knockdown ( Fig. 1 B- 
D).
We next employed a specific inhibitor of GBF-1, Golgicide A (GCA). GCA stabilizes GBF-1 on ER-Golgi membranes and interferes with ER-Golgi and intra-Golgi transport, and disperses the Golgi (54) . Twenty µM GCA dispersed Golgi in A549
cells, but had no strong effects on metabolic cell activity, shown by immunostaining of giantin and resazurin measurements, respectively ( Fig. 2 A, shortly before or after virus, essentially no boosting effect was observed, strongly suggesting that GBF-1 is not acutely involved in infection, but rather through a mechanism that takes hours to build up (Fig 2 G) . In further experiments we used a 5 h GCA pretreatment to induce the infection enhancing effect. Furthermore, both positive and negative feedback mechanisms control the expression of E1A (73), and thus the E1A protein levels in infected cells become stabilized after initial increase. GCA enhanced the expression of HAdV-C5 13S and 12S protein products at 5 h pi, and accelerated appearance of the 9S product at 5 and 9 h pi (Fig. 3 A) . In contrast, E1A levels in 293T cells, which harbor an integrated copy of the E1A region (15, 38) were not enhanced but rather reduced by
GCA, yet GCA boosted HAdV-C5-dE1_GFP infection in these cells, albeit less efficiently than in A549 cells ( 
GCA enhances cancer cell killing
We next tested whether inhibition of GBF-1 boosts HAdV infection of primary tumor stage III melanoma cultures M950822 and M980928, which are both CAR-positive (47, 55) . GCA enhanced HAdV-C5-dE1_GFP infection several fold in both cases but had little effects in normal human WI38 fibroblasts (Fig. 4 A) . GCA boosted the HAdV-C2-dE3B_GFP infection spread in M980928 cells measured by increase in number of infected cells at 48 h compared to 72 h pi in a live cell assay (Fig. 4 B) .
Crystal violet cell staining of HAdV-C5_wt infected M950822 and M980928 cells at 72 h pi also indicated that virus cytotoxicity was enhanced by the GCA pretreatment
To corroborate these results, we measured virus-induced changes to cell phenotypes by recording the impedance at the cell substrate interface using xCELLigence TM . Changes in impedance, also dubbed cell index (CI) can be measured in real time and label-free, and are proportional to parameters like cell adhesion, proliferation, cell-cell interactions, and cytotoxicity (58, 59). CI dropped as a linear function of log (MOI) upon infection with HAdV-C5_wt, but independent of the initial number of cells on the substrate (Fig. 5 A) . The replication-defective
HAdV-C5_dE1_GFP had less effects on CI than HAdV-C5_wt, and GCA pretreatment reduced the CI of HAdV-C5_wt infected A549 cells but had essentially no effects on CI of uninfected cells ( from Golgi membranes (69) , and that HRV-A1A requires lipid flux between the ER and Golgi for replication (51) .
IRE-1 and XBP-1 are required for GCA enhancement of HAdV infection
UPR enhances the protein folding capacity in the ER upon stress conditions, such as physical, chemical or biological insults, developmental processes or cancer (6).
ER stress activates three signaling arms of UPR, IRE-1/XBP-1, PKR-like ER kinase (PERK) and ATF-6 (37). This can lead to cell protection or cell death. The former is favored by the IRE-1 branch, and the latter by the ATF-6 and PERK arms (37) .
Since knockdown of GBF-1 has been shown to induce the ATF-6 arm of the UPR (11), we tested whether the UPR was linked to the GCA boost of HAdV infection.
The knock-down of IRE-1alpha with a pool of four siRNAs had the strongest effect on blunting GCA enhancement, although ATF-6B knock-down reduced the boost as well (Fig. 6 A) . We confirmed these results with a pool of 30 synthetic siRNAs (siPRNAs), which were reported to have no detectable off-target effects (26). The siP-IRE-1 RNAs blocked infection boost and reduced the IRE-1 protein levels (Fig. 6 B) .
The treatment of cells with GCA triggered the IRE-1/XBP-1 branch of the UPR, similar to the ER stress activator thapsigargin, as indicated by the activation of cytoplasmic splicing of XBP-1 mRNA, and this splicing was inhibited by the IRE-1 nuclease inhibitor 4µ8C (Fig. 6 C, 13 ). Similar to GCA, thapsigargin boosted HAdV-C5-dE1_GFP infection, and 4µ8C blunted both the GCA and thapsigargin boosts (Fig. 6 D) . For HAdV-C5-dE1_GFP, the GCA infection boost was strongly, but not completely reduced in XBP-1 knock-out mouse embryo fibroblasts (36) , akin to XBP-1 siP-RNA treated A549 cells ( (Fig. 7 A, B) . Importantly, siP-RNAs against IRE-1 or XBP-1 blunted the GCA enhancement of comet formation ( Fig. 7 C, D) . Notably, these siP-RNAs reduced the number of comets also without GCA treatment, were controlled by Western blotting using β-tubulin as a loading control. 
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